Vontobel Holding Ltd. Buys New Position in Humacyte, Inc. (NASDAQ:HUMA)

Vontobel Holding Ltd. purchased a new position in shares of Humacyte, Inc. (NASDAQ:HUMA) during the fourth quarter, Holdings Channel.com reports. The fund purchased 10,000 shares of the company’s stock, valued at approximately $50,000.

Other hedge funds have also made changes to their positions in the company. Brookstone Capital Management acquired a new position in shares of Humacyte in the fourth quarter valued at approximately $56,000. ACT Wealth Management LLC acquired a new position in shares of Humacyte in the fourth quarter worth $57,000. Concurrent Investment Advisors LLC acquired a new position in shares of Humacyte in the third quarter worth $75,000. FORA Capital LLC purchased a new stake in shares of Humacyte during the third quarter worth $96,000. Finally, Insigneo Advisory Services LLC acquired a new position in Humacyte during the 3rd quarter worth $109,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on HUMA. Benchmark increased their price target on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, December 23rd. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Humacyte presently has an average rating of “Buy” and an average price target of $13.71.

Humacyte Stock Performance

HUMA opened at $3.55 on Friday. Humacyte, Inc. has a one year low of $2.81 and a one year high of $9.97. The company has a market cap of $446.17 million, a P/E ratio of -2.65 and a beta of 1.30. The business’s 50-day simple moving average is $4.42 and its 200-day simple moving average is $5.12.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.